C402-CD19-CAR

· Shanghai Exuma Biotechnology Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for C402-CD19-CAR, covering 2025-06-13 to 2025-06-13. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma [Phase 1]